All News

The risk of cardiovascular disease (CVD) was higher among those who were exposed to assisted reproductive technology.

The treatment could hold significant potential for major depressive disorder

The combination demonstrated improved efficacy compared with ruxolitinib as a monotherapy.

Research reveals pioglitazone, a diabetes drug, may slow prostate cancer progression, offering new hope for patients with both conditions.

Glofitamab combined with GemOx shows promising survival benefits for patients with relapsed DLBCL, offering a new treatment option for those ineligible for transplants.

A new triple-combination therapy shows promise in improving asthma management, offering hope for millions with uncontrolled symptoms.

Don Moore, PharmD, BCPS, BCOP, DPLA, FCCP, FASHP, received a leadership award at the 2025 HOPA Annual Meeting.

A systematic review reveals declining pediatric pneumococcal complicated pneumonia rates following the introduction of pneumococcal conjugate vaccine 13.

Diabetic ketoacidosis poses serious risks for patients with diabetes, requiring urgent treatment to prevent life-threatening complications and ensure recovery.

Health care professionals play a vital role in preventing overdose and ensuring safe use.

Compared with placebo, patients with cholestatic pruritus and primary biliary cholangitis (PBC) receiving linerixibat experienced improved itch and sleep interference.

Motivational interviewing serves as a beneficial strategy to enhance medication adherence and improve patient outcomes in diabetes management.

Host Craig Beavers speaks with Orly Vardeny, PharmD, MS, a professor of medicine at the University of Minnesota

New research highlights the effectiveness and safety of RSV vaccines for older adults, revealing critical insights into vaccination benefits and risks.

Pharmacists compare real-world practice data with clinical trial results and discuss supportive care options for patients.

The authors believe the results may serve as a foundation for hepatitis D virus (HDV) testing among hepatitis B virus surface antigen (HBsAg)-positive specimens.

The approval expands the therapy’s indication to children as young as 7 years.

A study reveals sasanlimab enhances event-free survival in high-risk bladder cancer patients, offering new hope against disease recurrence.

Pharmacists should continue to emphasize the vaccine’s effectiveness in preventing cancer and be prepared to address patient safety concerns.

COVID-19 can reshape one’s academic journey and outlook on life.

The Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio is the first in vitro diagnostic device that tests blood to aid in diagnosing Alzheimer disease.

The vaccine, indicated with a restriction on use for those younger than 65 years and without comorbidities, was proven safe and effective in a series of large clinical trials, and marks the first protein-based vaccine to be approved in the United States.

Patients should understand that routine skin care is an important facet in the overall management of diabetes.

Naxitamab-gqgk has been added as a Category 2A recommendation in the updated National Comprehensive Cancer Network (NCCN) guidelines for high-risk neuroblastoma, reflecting growing consensus on its role in treating relapsed or refractory disease.

Cynthia Ryan, PharmD, BCPS, discusses practical, evidence-based strategies for pharmacists to identify, prevent, and manage dermatologic toxicities associated with cancer therapies, emphasizing interdisciplinary collaboration, patient education, and proactive supportive care to improve adherence and outcomes.

Aficamten, a cardiac myosin inhibitor, gains FDA approval, offering hope for improved cardiovascular health in patients with obstructive hypertrophic cardiomyopathy.

Implementation of a guidance document for periprocedural antibiotic prophylaxis resulted in improved appropriateness of antibiotic dose, selection, and duration for interventional radiology procedures.

New data reveals that combining pertuzumab with trastuzumab significantly improves survival rates in HER2+ breast cancer patients, reducing death risk by 17%.

Advocacy fosters professional development, creates better working conditions, and enhances patient care.